GAS5 and metabolic dysfunction-associated steatotic liver disease: Han et al. experimentally confirmed that plasma lncRNA GAS5 was significantly elevated in patients with advanced fibrosis compared to patients without progressive fibrosis, but this did not show any statistical difference in tissues, but lncRNA GAS5 tissue expression was positively correlated with the stage of fibrosis prior to the development of cirrhosis as well as significantly downregulating lncRNA in plasma of NAFLD patients with cirrhosis GAS5 expression (Han et al., 2020).